The biotech’s efforts to bring its vaccines to the country mean navigating political pushback in the U.S. and the risk of ...

A new weight loss biotech launched with $410 million and three assets from China. Roche's Chugai penned a deal to develop ...

It specifies that by 2035, China expects to fully ensure the safety, efficacy, and accessibility of drugs and medical devices ...

The Chinese foreign ministry said on Friday that it had maintained close communication with the World Health Organization ...

Anti-corruption campaign brings down senior health officials, hospital directors, academics, and pharmaceutical company ...

10 Stocks to Sell NOW! 3 Stocks to DOUBLE This Year The 10 Best Stocks to Own in 2023 7 Stocks to Buy and Hold Forever China Pharma Holdings, Inc develops, manufactures, and markets generic and ...

Astellas Pharma Inc. announced that China’s National Medical Products Administration (NMPA) has approved Padcev (enfortumab vedotin) in combination with Keytruda (pembrolizumab) for adult patients ...

Rising cases of common respiratory illnesses in China and elsewhere around the Northern Hemisphere are within the range ...

(RTTNews) - Astellas Pharma Inc. (ALPMY, ALPMY) announced that China's National Medical Products Administration approved VYLOY (zolbetuximab), in combination with fluoropyrimidine- and platinum ...

President-elect Trump’s plan to enact heavy tariffs on certain imports could affect the prices and availability of ...

HUTCHMED (China) agrees to divest its 45% stake in Shanghai Hutchison Pharma for $608M in cash to a group including Shanghai ...